Exelixis in the NEWS  

Two days ago, Exelixis (EXEL) reported financial results for the first quarter of 2025, providing an update on the firm’s progress toward achieving key corporate objectives, and outlined its commercial, clinical, and pipeline development milestones.
From Exelixis
Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis said, " Exelixis has delivered outstanding financial performance . . .